… treatment strategy. Thus, we present here an update on the role of p38 MAPK in
neurodegeneration, with a focus on Alzheimer's disease, by summarizing recent literature and …

… diseases. Since the identification of the prototypical p38 MAPK inhibitor 1 in 1994, numerous
p38 MAPK … P38 MAPK inhibitors vary markedly in both chemical structure and binding …

… members of the p38 MAP kinase family 19, 42. In neuronal systems many stimuli that increase
… In human neuroblastoma SH-SY5Y cells treatment with osmotic stress resulted in a robust …

… on p38 MAPK and AD pathophysiology section, we focus on therapeutic targeting of p38
MAPK in … Small molecular p38 MAPK inhibitors have been applied to treat inflammatory …

… improvement of outcomes with treatments that decrease cytokine levels. … p38 MAPK active
site, we introduced into the scaffold a pyridinyl pharmacophore found in a variety of p38 MAPK …

… tissue from control and Alzheimer’s disease (AD) cases at … Taken together, this study
demonstrates that p38 MAPK is … , the sections were also treated before the blocking step with …

… the p38 MAPK cascade is activated either in response to the Aβ peptide or in the presence of
tauopathies. Here, we describe the role of p38 MAPK … target for the treatment of AD [11,44]. …

… synthase kinase (GSK3), p38 mitogen-activated protein kinase (MAPK) and some of the …
the two neurodegenerative disorders. The potential of targeting GSK3, p38 MAPK and CDKS as …

… for treating AD in the future. This brief review will focus on … -molecule inhibitors of p38
MAP kinase have been utilized to … cycle-related events in Alzheimer disease. J. Neuropathol. …

… binds to an active form of p38 MAPK. PRZ-18002 induces degradation of phosphorylated
p38 MAPK (p-p38) and a phosphomimetic mutant of p38 MAPK in a proteasome-dependent …